170 related articles for article (PubMed ID: 35488144)
1. Regional Differences in the Absolute Abundance of Transporters, Receptors and Tight Junction Molecules at the Blood-Arachnoid Barrier and Blood-Spinal Cord Barrier among Cervical, Thoracic and Lumbar Spines in Dogs.
Takeuchi H; Suzuki M; Goto R; Tezuka K; Fuchs H; Ishiguro N; Terasaki T; Braun C; Uchida Y
Pharm Res; 2022 Jul; 39(7):1393-1413. PubMed ID: 35488144
[TBL] [Abstract][Full Text] [Related]
2. A human blood-arachnoid barrier atlas of transporters, receptors, enzymes, and tight junction and marker proteins: Comparison with dog and pig in absolute abundance.
Uchida Y; Takeuchi H; Goto R; Braun C; Fuchs H; Ishiguro N; Takao M; Tano M; Terasaki T
J Neurochem; 2022 Apr; 161(2):187-208. PubMed ID: 35226354
[TBL] [Abstract][Full Text] [Related]
3. Abundant Expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT Transporters in Blood-Arachnoid Barrier of Pig and Polarized Localizations at CSF- and Blood-Facing Plasma Membranes.
Uchida Y; Goto R; Takeuchi H; Łuczak M; Usui T; Tachikawa M; Terasaki T
Drug Metab Dispos; 2020 Feb; 48(2):135-145. PubMed ID: 31771948
[TBL] [Abstract][Full Text] [Related]
4. Drug Clearance from Cerebrospinal Fluid Mediated by Organic Anion Transporters 1 (Slc22a6) and 3 (Slc22a8) at Arachnoid Membrane of Rats.
Zhang Z; Tachikawa M; Uchida Y; Terasaki T
Mol Pharm; 2018 Mar; 15(3):911-922. PubMed ID: 29436232
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Absolute Protein Abundances of Transporters and Receptors among Blood-Brain Barriers at Different Cerebral Regions and the Blood-Spinal Cord Barrier in Humans and Rats.
Uchida Y; Yagi Y; Takao M; Tano M; Umetsu M; Hirano S; Usui T; Tachikawa M; Terasaki T
Mol Pharm; 2020 Jun; 17(6):2006-2020. PubMed ID: 32310660
[TBL] [Abstract][Full Text] [Related]
6. [Molecular Mechanism Underlying the Function and Disintegration of the Central Nerve System Barrier Unraveled by Proteo-typing of Membrane Proteins].
Terasaki T
Brain Nerve; 2021 Jan; 73(1):59-78. PubMed ID: 33361514
[TBL] [Abstract][Full Text] [Related]
7. Inner Blood-Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig.
Zhang Z; Uchida Y; Hirano S; Ando D; Kubo Y; Auriola S; Akanuma SI; Hosoya KI; Urtti A; Terasaki T; Tachikawa M
Mol Pharm; 2017 Nov; 14(11):3729-3738. PubMed ID: 28954515
[TBL] [Abstract][Full Text] [Related]
8. Organic Anion-Transporting Polypeptide 1a4 (Oatp1a4/Slco1a4) at the Blood-Arachnoid Barrier is the Major Pathway of Sulforhodamine-101 Clearance from Cerebrospinal Fluid of Rats.
Yaguchi Y; Tachikawa M; Zhang Z; Terasaki T
Mol Pharm; 2019 May; 16(5):2021-2027. PubMed ID: 30977661
[TBL] [Abstract][Full Text] [Related]
9. Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen.
Uchida Y; Zhang Z; Tachikawa M; Terasaki T
J Neurochem; 2015 Sep; 134(6):1104-15. PubMed ID: 25951748
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Claudin-11 in Disruption of Blood-Brain, -Spinal Cord, and -Arachnoid Barriers in Multiple Sclerosis.
Uchida Y; Sumiya T; Tachikawa M; Yamakawa T; Murata S; Yagi Y; Sato K; Stephan A; Ito K; Ohtsuki S; Couraud PO; Suzuki T; Terasaki T
Mol Neurobiol; 2019 Mar; 56(3):2039-2056. PubMed ID: 29984400
[TBL] [Abstract][Full Text] [Related]
11. Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier.
Yasuda K; Cline C; Vogel P; Onciu M; Fatima S; Sorrentino BP; Thirumaran RK; Ekins S; Urade Y; Fujimori K; Schuetz EG
Drug Metab Dispos; 2013 Apr; 41(4):923-31. PubMed ID: 23298861
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Targeted Absolute Proteomics for Better Characterization of an In Vitro Human Blood-Brain Barrier Model Derived from Hematopoietic Stem Cells.
Dehouck MP; Tachikawa M; Hoshi Y; Omori K; Maurage CA; Strecker G; Dehouck L; Boucau MC; Uchida Y; Gosselet F; Terasaki T; Karamanos Y
Cells; 2022 Dec; 11(24):. PubMed ID: 36552728
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery.
Huttunen KM; Terasaki T; Urtti A; Montaser AB; Uchida Y
Pharm Res; 2022 Jul; 39(7):1363-1392. PubMed ID: 35257288
[TBL] [Abstract][Full Text] [Related]
14. The ROCK inhibitor Y-27632 ameliorates blood-spinal cord barrier disruption by reducing tight junction protein degradation via the MYPT1-MLC2 pathway after spinal cord injury in rats.
Chang S; Cao Y
Brain Res; 2021 Dec; 1773():147684. PubMed ID: 34634287
[TBL] [Abstract][Full Text] [Related]
15. Pathological hemodynamic changes and leukocyte transmigration disrupt the blood-spinal cord barrier after spinal cord injury.
Zhou R; Li J; Chen Z; Wang R; Shen Y; Zhang R; Zhou F; Zhang Y
J Neuroinflammation; 2023 May; 20(1):118. PubMed ID: 37210532
[TBL] [Abstract][Full Text] [Related]
16. Developmental changes in transporter and receptor protein expression levels at the rat blood-brain barrier based on quantitative targeted absolute proteomics.
Omori K; Tachikawa M; Hirose S; Taii A; Akanuma SI; Hosoya KI; Terasaki T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):117-123. PubMed ID: 31974045
[TBL] [Abstract][Full Text] [Related]
17. Blood-spinal cord barrier leakage is independent of motor neuron pathology in ALS.
Waters S; Swanson MEV; Dieriks BV; Zhang YB; Grimsey NL; Murray HC; Turner C; Waldvogel HJ; Faull RLM; An J; Bowser R; Curtis MA; Dragunow M; Scotter E
Acta Neuropathol Commun; 2021 Aug; 9(1):144. PubMed ID: 34446086
[TBL] [Abstract][Full Text] [Related]
18. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability.
Winkler EA; Sengillo JD; Bell RD; Wang J; Zlokovic BV
J Cereb Blood Flow Metab; 2012 Oct; 32(10):1841-52. PubMed ID: 22850407
[TBL] [Abstract][Full Text] [Related]
19. A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice.
Uchida Y; Tachikawa M; Obuchi W; Hoshi Y; Tomioka Y; Ohtsuki S; Terasaki T
Fluids Barriers CNS; 2013 Jun; 10(1):21. PubMed ID: 23758935
[TBL] [Abstract][Full Text] [Related]
20. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model.
Ohtsuki S; Ikeda C; Uchida Y; Sakamoto Y; Miller F; Glacial F; Decleves X; Scherrmann JM; Couraud PO; Kubo Y; Tachikawa M; Terasaki T
Mol Pharm; 2013 Jan; 10(1):289-96. PubMed ID: 23137377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
